Search clinical trials for: Influenza Virus Vaccine USP Trivalent Types A and B

Total 755 results

Sanofi Pasteur, a Sanofi Company

Completed

Influenza Vaccine Revaccination in Ambulatory Elderly Subjects

Influenza | Myxovirus Infection | Orthomyxovirus Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM

Influenza

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
Atopic Dermatitis Research Network

Completed

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study

Dermatitis, Atopic

United States
Roswell Park Cancer Institute

Completed

Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Shanghai Institute Of Biological Products

Completed

A Clinical Trial of A Quadrivalent Influenza Vaccine

Influenza

China
Jiangsu Province Centers for Disease Control and...
Jiangsu Jindike Biotechnology Co., Ltd.

Completed

A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and Older

Influenza

China
Emory University
National Cancer Institute (NCI); Sanofi; National Institutes of Health (NIH)

Completed

Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders

Plasma Cell Neoplasm

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Influenza Virus Vaccines in Children and Adults

Influenza

United States
Seqirus
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older

Influenza

Belgium
Butantan Institute
Fundação Butantan

Recruiting

Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .

Influenza, Human

Brazil
Novartis
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects

Pandemic Influenza Disease

Finland, Germany
MedImmune LLC

Completed

A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children

Healthy

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years

Influenza

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors

Glioma | Astrocytoma | Oligodendroglioma

United States
Novartis Vaccines

Completed

Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years Old

Influenza

Dominican Republic
British Columbia Centre for Disease Control

Completed

Influenza Vaccine Dose-Response in Infants and Toddlers: Immunogenicity and Reactogenicity (TITRE)

Influenza

Canada
MedImmune LLC

Completed

A Phase 2 Study to Evaluate Immune Responses of FluMist®

Influenza Vaccine

United States
Sinovac Biotech Co., Ltd

Completed

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)

Seasonal Influenza

China
Sinovac Biotech Co., Ltd

Completed

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)

Seasonal Influenza

China
Shanghai Institute Of Biological Products

Completed

Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

Influenza

China
National Institute of Allergy and Infectious Diseases...

Completed

Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

FLU-VACS Comparative Study in Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

Influenza

United States
MedImmune LLC

Completed

A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine (MI-MA182)

Influenza

United States
Seqirus

Completed

A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years

Influenza, Human

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above

Human Influenza

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults Aged 18 Years and Above

Influenza | Human

Germany
MedImmune LLC
AstraZeneca

Completed

A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Influenza

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects

Human Influenza

Belgium
Sanofi Pasteur, a Sanofi Company

Completed

Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age

Influenza

China
Masonic Cancer Center, University of Minnesota

Terminated

Influenza Vaccine Post Allogeneic Transplant

Hematologic Malignancy | Hematopoietic Stem Cell Transplant

United States
Seqirus
Novartis Vaccines

Completed

Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.

Influenza Virus

United States, Canada, Finland, Italy, Mexico, Philippines, Poland, Puerto Rico, Spain, Taiwan, Thailand
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old

Influenza

United States, Finland, Philippines, Thailand
Seqirus

Completed

A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

Influenza, Human

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine

Influenza

United States
Sinovac Biotech Co., Ltd

Recruiting

A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months

Seasonal Influenza

China
Sinovac Biotech Co., Ltd

Completed

A Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months

Seasonal Influenza

China
Sanofi Pasteur, a Sanofi Company

Completed

Study of Quadrivalent Influenza Vaccine Among Children

Influenza

United States
Sinovac Biotech Co., Ltd

Completed

Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, Adults

Influenza

China
Hvivo
Pfizer

Recruiting

Dose, Safety, and Pathogenicity of a New Influenza B Strain

Influenza B

United Kingdom
Center for Disease Prevention and Control of Beijing...

Completed

Safety and Immunogenicity of Three Seasonal Trivalent Influenza Vaccines in China Military

Influenza

China
Beijing Chaoyang District Centre for Disease Control...

Unknown

Safety and Immunogenicity Study of Quadrivalent Influenza Virus Vaccine in Healthy People Aged Years 3-60

Quadrivalent Influenza Virus Vaccine
National Institute of Allergy and Infectious Diseases...

Completed

H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses

Influenza | Avian Influenza | H1N1 Influenza

United States
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above

Influenza

Germany
National Institute of Allergy and Infectious Diseases...

Completed

Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US

Influenza

United States
Sanofi

Completed

Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years

Influenza | Flu

China
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age

Influenza Disease

Argentina, Australia, Chile, Philippines, South Africa
Guangxi Zhuang Autonomous Region Center for Disease...
Air Force Military Medical University, China; Beijing Tiantan Biological Products...

Completed

Randomized Controlled Trial for Immunogenicity and Safety Evaluation of Bivalent Types 1 and 3 Oral Poliovirus Vaccine (TTbOPV)

Poliomyelitis

3

Subscribe